Voluntary announcement envafolimab supplemental application for conditional-to-regular approval transition approved by NMPA
Filed with HKEX · Stock code 1244 · · 2 pages · English
Earlier from 3D Medicines
- Voluntary announcement latest progress in collaboration programs: positive data achieved in the Global Pivotal Phase 3 REGAL trial for 3D189
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement latest progress in collaboration programs: achievement of pre-specified number of events in the global pivotal phase 3 REGAL trial for 3D189
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Change of principal share registrar and transfer office
Follow 3D Medicines into a list and get an email when it puts out news.
Follow 3D Medicines